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This paper considers the use of diagnostic techniques for Chlamydia pneumoniae in both acute and chronic infections, 
together with the detection of upper respiratory tract carriage. It is concluded that such diagnosis is still unsatisfactory, 
although techniques for acute infection are more reliable than those for chronic conditions. Reliable and inexpensive 
methods, particularly for the diagnosis of chronic C. pneumoniae infection, are urgently needed, if only because of the 
recent demonstration of the beneficial effects of antibiotic treatment in  patients with atherosclerosis carrying markers 
for the presence of this organism. 
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Chlamydia pneumoniae can cause carriage, acute 
infections, and chronic infections. These entities 
overlap, and because of difficulty in sampling from the 
site of infection, insensitive culture methods, and 
expertise-demanding serology, the diagnosis of these 
common infections is confusing, if the behavior of the 
agent is not known [1,2]. 
ACUTE CHLAMYDIA PNEUMONIAE INFECTIONS 
Culture 
The general experience is that the culture of C. 
yneumoniue is difficult, and only one laboratory has 
recommended it as a standard of diagnosis. HL [3,4] 
and Hep-2 [5] cells are most commonly used at present. 
The amount of cycloheximide used is critical [6], and 
it has been claimed that fetal calf serum can be excluded 
from the cell-culture medium [7]. Blind passages are 
recommended. In cell cultures, C. pneumoniue behaves 
like C. psittaci [8]. It  also resembles C. psittaci in that 
it can cause both asymptomatic and symptomatic 
laboratory infections [9,10]. 
Culture of clinical samples has been a disappoint- 
ment. In cases verified by serology, the sensitivity of 
isolation has been about 50% [ll-161. There could be 
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several reasons for this result. The ideal cell line for C. 
pneumoniae isolation may not have been found. 
Circulating strains may vary considerably in their ability 
to grow in cell cultures, and serologic findings can 
depend on the method used and the population 
studied. As a rule, in primary isolations, only a few 
inclusions are found. There is a possibility that only a 
few C. pneumoniae elementary bodies (EBs) in the 
sample are able to induce an inclusion. Another 
possible explanation is that the true number of infecting 
EBs is initially low, leading to the small amount of C. 
pneumoniae organisms in throat epithelium samples 
collected by swabbing. This latter assumption is 
supported by the low sensitivity of other diagnostic 
methods based on the direct demonstration of the 
organism or its components in throat swabs. Naso- 
pharyngeal swabs have been recommended in some 
studies [5] but others have not found them to be of any 
advantage [17] Pretreatment of samples has been 
recommended [18]. The principal multiplication site of 
C. pneumniue can be other than the superficial 
epithelium of the respiratory tract. When the pathogen 
invades deeper tissues, obtaining a proper sample can 
be more difficult. Since cough is usually non-produc- 
tive, sputum samples are often difficult to obtain and 
thus induced sputa or bronchoalveolar lavages (BALs) 
are needed. 
Antigen detection 
Lipopolysaccharide enzyme immunoassay 
AU commercial enzyme immunoassay (EIA) kits for the 
diagnosis of C. tvachomutis infection detect lipo- 
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polysaccharide (LI'S) group antigen coninion to all 
chlamydia [19] and can thus be tried for detection of C. 
yrierrrnoniac LPS from respiratory tract samples. This 
must be kept in mind when using EIA to diagnose infant 
pneumonitis caused by C. trarhomaris. Positive reactions 
can be caused by C. prieirrnoniae. which has been isolated 
from infants <6 months of age. Some published reports 
point to a limited amount of LPS in throat swabs. 
Nothing is known about possible cross-reactions with 
normal throat flora. Final identification should be done 
by fluorescence microscopy. Only a few comparative 
studies of the value of EIA antigen test5 have so far been 
done (20,211; according to Boman et al [ 171, they can 
be used especially for sputum samples. if obtained. 
Direct fluorescent antibody staining 
Direct fluorescent antibody (DFA) staining, which has 
been successfully used in C. truchomtis  diagnosis, has 
been shown to be insensitive in the demonstration of 
C. pneuriioniae in throat swabs [ l l] .  The pharyngeal 
flora is quite variable, and minute numbers of EBs are 
difficult to detect. The EBs cannot tolerate the harsh 
treatment of EIA samples like C. traclzounatic EBs. and 
fixation with slime-destroying methanol is deleterious 
for EBs [22].  Modifications of DFA tests include 
indirect staining with specific IgM antibodies 1231 
which do not bind to protein A-containing bacteria, 
and the use of sediments of gargling water, free of 
interfering slime [24]. The sensitivity of DFA coni- 
pared to isolation, PCR and serology has remained low 
(20-60'%) [11,17,23], and specificity is completely 
dependent on the skill of the interpreter. However, in 
severe pneumonia, IIFA staining can help in finding the 
proper treatment [2S]. 
Serology 
In C. prieurnoiiiue infections, the first antibodies to 
appear are those against chlamydia1 LPS. Kesponse to 
protein antigens can be delayed and IgM antibodies 
against protein antigens are usually seen only in primary 
infections [26]. IgA antibody response is marked only 
in reinfections [14]. Serology has so far been the most 
conimonly used method for diagnosis of C. prieurnorzine 
infections. In most studies, it has been the most 
sensitive method, but, with a few exceptions, the need 
for paired serum samples lessens its value. In 
epidemiologic studies, it has been the most important 
method. 
Complement fixation 
The complement-fixation (CF) test was earlier thought 
to be diagnostic in C. psittaci infection (and to a lesser 
extent in lymphogranuloma venereum (LGV), but it 
has been shown recently that in some epidemics the 
niajority of CF-positive case5 \\ere in fact C pncir- 
rnmiiae infections 127-291 However, the CF test is 
reliably positive only in primary C przetirnoniae infec- 
tions of young adults, and misses 90% of even severe 
reinfections [12-14,301 
EIA-antibody tests 
EIA-antibody tests based 011 EB antigen contain LPS 
connnon to all chlamydia. and the specificity of the test 
has been improved by removing or destroying LPS [31]. 
Chemically pure antigens would be ideal in EIA tests. 
So far, these have been derived only from chlaniydial 
LPS. The observed cross-reaction with Ke-LPS of 
mutant enterobacteria [32] has been utilized in develop- 
ing an EIA for measuring LPS antibodies [13,14]. This 
has been used in pneumonia studies, and it seems to be 
a sensitive test for diagnosis of chlaniydial pneumonias 
in general. An advantage is the rapid development of 
anti-LPS antibodies early in the infection, providing 
diagnosis in 5 days and making a paired sample taken 
LIP to a month later unnecessary. A coniniercial test 
based on recombinant LPS [34] has also appeared on 
the market, and is currently under evaluation [3S]. 
However, these tests lack species specificity. 
Microimmunofluorescence test 
The microimmunofluorescence (MIF) test of Wang 
and Grayston [36], which involves indirect imniuno- 
fluorescence of purified chlamydia1 EBs, can be 
interpreted as accepting all types of fluorescence, and it 
then lacks specificity [37.38]. Carriage can also lead to 
claims of insensitivity [9]. Performed with expertise and 
with properly collected paired sera, it is, so far, the most 
sensitive test for diagnosis of C. ptzeumoiiiue infection, 
even more sensitive than P C R  from throat specimens 
[ 15,231. Numerous seroepideniiologic studies have 
demonstrated the independence of C. przcummiue and 
C. trachomacis antibodies from each other and their 
different distributions in relation to age and sex [16,39]. 
Clainis of cross-reactivity are often based on the fact 
that if the reader accepts all area? of bright fluorescence 
and not only the even, homogeneous ones, then 
fluorescence due to cross-reactive LPS antibodies is 
accepted. Moreover, this reaction tends to be of the 
IgM type, and if the presence of IgM antibodies is 
accepted as being diagnostic for acute infections, this 
leads to false-positive diagnoses. Chlamydia1 LPS cross- 
reacts to some extent with Bavtoriella LPS, and this may 
present a diagnostic problem. Moreover, C. prienimniae 
antigens can be contaminated with Mycoplasrna species 
[40], again leading to false-positive findings, if all posi- 
tive fluorescence is accepted. 
Chlaniylal antibodies are rare in children, but at 
school age antibodies against C. pneurnoniae rapidly 
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begin to accumulate, especially in males. The situation 
can be different in acute conditions. It is possible that 
small children, after their first chlamydial infection, 
develop antibodies against surface protein antigens 
reactive in the MIF test only very slowly, in small 
amounts, or with restricted specificity, reacting with 
the causative strain only [41]. Effective antibiotic 
therapy can also prevent antibody formation [42]. Later, 
in teenagers and adults, MIF seems to be the most 
useful test for diagnosing an acute C. pneumoniae 
infection. In primary infections, the diagnosis can be 
obtained from the first sample with C. pneumoniae- 
specific IgM antibodies. The possible presence of IgM 
rheumatoid factor should always be kept in mind, 
especially in elderly patients [43]. There are also other 
possible reasons for false-positive findings. In primary 
chlamydial respiratory infections, older children and 
adults react strongly against the group antigen and the 
immunofluorescence pattern is quite difficult to 
interpret, leading to decreased specificity. In elderly 
patients undergoing reinfections, the rapid response can 
be missed if the first serum sample is not collected early 
enough during the convalescence. 
Since the test is subjective and depends on the 
antigens, conjugates, incubation periods and micro- 
scope that are used, and above all on the reader, exact 
titer limits for ‘significant’ findings cannot be given, but 
are dependent on the laboratory performing the test. 
Circulating immune complexes 
The presence of specific circulating immune complexes 
(CICs) in pneumococcal respiratory tract infections has 
been shown to be associated with pneumococcal 
pneumonia [44,45]. Also in C. pneumoniae pneumonias, 
specific CICs can be detected in patient sera (Leinonen 
et al., unpublished data). However, since arteriosclerosis 
is a common condition, especially in elderly males, the 
diagnostic value of these complexes in acute infections 
is minimal [46]. 
Nucleic acid detection 
There are several reports on the use of P C R  in the 
diagnosis C. pneumoniae infection [15-17,23,47-521. 
Compared to culture, P C R  has been very specific and 
more sensitive, and in future will be the standard diag- 
nostic method. However, easily obtainable throat swabs 
do not seem to be ideal for nucleic acid (NA) detection, 
since serology has sometimes been shown to be more 
sensitive [15,23]. It is possible that in slowly developing, 
biphasic C. pneumoniae pneumonia, the amount of the 
agent in upper throat epithelium is minute, and dry 
cough does not produce a sufficient amount of the 
agent from a deep-sited pneumonic infiltrate. Sputum 
is the best source for NA detection [17]. 
UPPER RESPIRATORY TRACT CARRIAGE 
In the carrier state, the agent can be detected (e.g. in 
throat samples) but it has no connection with the actual 
disease of the patient. Since chlamydiae are obligatory 
intracellular pathogens, whose multiplication cycle 
includes the rupture of chlamydial inclusions with 
associated cell death for liberation of infective EBs, they 
are not harmless commensals. Slow replication can, 
however, take place in sites where target cells are 
multiplying so rapidly that no apparent damage is 
found. Moreover, expulsion of chlamydial inclusions 
without cell death has been described, but it is not 
known if this also happens in C. pneumoniae infections. 
A new, interesting finding is the ability of C. pneumoniae 
to multiply inside amebae, which can form a part of the 
normal flora in the mouth. This could lead to a ‘true’ 
carrier state in the host. 
DIAGNOSIS OF CHRONIC INFECTIONS 
Although the diagnosis of acute C. pneumoniae 
infection is difficult, the real problem is the diagnosis 
of the chronic infections which it might cause. Studies 
on antibody prevalences in industrialized countries 
have shown that, in the general population, antibodies 
against C. pneumoniae are by far the most common and 
are present in the highest titers. These high titers can 
partly be explained by a booster effect due to reinfec- 
tion but they may also suggest chronic infections, by 
analogy with deep-sited chronic C. trachomatis infec- 
tions. C. pneumoniae readily invades lungs and, if it 
persists there, a chronic chlamydial inflammation may 
lead to severe complications. Moreover, in normally 
sterile lungs there is an intimate association with the 
circulatory system, offering a route of systemic dis- 
semination to more distant sites. 
If the amount of infective agent in acute C. 
pneumoniae infection seems quite low in most cases, it 
could be still lower in chronic infections. The most 
difficult situation is the possibility of a ‘hit-and-run’ 
event, where the agent has triggered an abnormal 
reaction causing the disease, although the inducer has 
disappeared from the site. 
Culture 
It is well known from C. trachomatis studies that in 
chronic infections chlamydial culture is insensitive, 
although otherwise the agent is relatively easy to 
cultivate [53,54]. This is understandable, because in 
chronic infections the lesion is loaded with products of 
activated defense mechanisms. In isolation, chlamydia 
are liberated from cells which have been protecting 
them and become a vulnerable target for neutralizing 
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mechanisms. C. pneurnoniae is difficult to isolate even in 
acute conditions, and negative isolation does not 
exclude suspected chronic infections 1551. However, 
isolation percentages of up to 12% for C. pneumoniae 
from atherosclerotic lesions have recently been reported 
[56]; this is comparable to that for C. tvachomatir in 
chronic trachoma. 
Serology 
Serologic findi~igs have shown that C. pneutnoniae 
infections do not behave like C. traclzomatis infections 
in general and they point to a possibility of chronic, 
generalized infections. Serology as an indicator of 
chronic infection is, however, far from optimal. First, it 
tells us nothing of the location of a possible chronic 
process. Second, C. pnecimoniae antibodies are common, 
especially in older age groups, and thus demonstration 
of an association with a particular disease can be 
difficult. Third, epidemics also induce antibodies in 
‘control’ populations. However, continuously elevated 
high-titer antibodies can be, if not a sign of a chronic 
infection, at  least a sign of defense mechanisms going 
‘awry’ in the process of defending against an intra- 
cellular pathogen, for which cell-mediated immunity 
can be crucial. Antibodies can be measured from local 
secretions, giving clues as to what is happening in the 
areas in question, and can therefore be illustrative in 
chronic bronchitis and asthma associated with C. 
pneiimonine 157,581. 
MIF has provided the first evidence of the possible 
association of C. pneirinouiae infection with various 
chronic inflammatory processes [59,60]. ‘Unspecific’ 
antibody tests, such as particle-, LPS EIA- and 
inclusion-based serologic tests, being broadly reactive 
and sensitive to the common chlamydial antigens 
presented to the host in the course of chronic 
infections, are (paradoxically perhaps) more sensitive 
for monitoring chronic chlamydial infections. 
Immunoblotting offers the possibility of measuring 
specific responses to various chlamydial antigens 
[61-63]. How specific the reactions are is doubtful, 
since chlamydial proteins possess common epitopes 
which are exposed and reactive after PAGE electro- 
phoresis. However, these studies should be continued 
in  order to find those proteins reactive in chronic 
infections, especially those belonging to the hsp fanllly 
[33].  These proteins could then be used as antigens in 
EIA to detect any patients with persistent infection. 
immune complexes 
The consistent presence of immune complexes is a sign 
of continuous production of new complexes inside the 
body, i.e. continuous production of microbial antigens, 
and thus a persistent infection. These kinds of con-  
plexes are typical for chronic infections and their 
presence is well documented in many viral and bacterial 
chronic diseases. Two kinds of immune complexes have 
been reported in suspected chronic chlamydial infec- 
tions, those containing chlamydial LPS and respective 
antibodies [44,45], the majority of the IgM type, and 
those containing antibodies against chlamydial proteins 
[46]. The presence of LPS immune complexes does not 
provide information about the localization of the 
chronic infection, since LPS is easily transported in the 
body and can pass through cell layers into the 
circulation. No corresponding transport mechanism is 
known for bacterial proteins. Immune complexes 
containing bacterial proteins and their antibodies in the 
blood circulation point to the actual presence of the 
agent in the bloodstream or, as in the case of C. 
pneumoniae, in circulating blood cells, vascular 
endothelium, or the areas where damaged endothelium 
allows the release directly into the bloodstream of 
chlamydial proteins produced during a chronic 
infection. 
Immune complexes containing chlamydial proteins 
are not easy to demonstrate. The precipitation of 
complexes is easily interfered with, co-precipitating 
free antibodies causing false-positive findings when 
immune complex-bound antibodies are measured. The 
presence of immune complexes does not reveal the 
exact locality of the chronic process, i.e. whether it is 
situated on the venous or the arterial side of the 
circulation. However, a simplified test for specific 
immune complexes would be useful, because it could 
perhaps determine which individuals are suspected of 
harboring chlamydia in their blood vessels. They could 
be followed to establish whether the process is slow and 
cures spontaneously, or continuously worsens. 
Antigen detection 
Antigen detection has already shown its power when 
compared to isolation in chronic C. tvachornatis infec- 
tions. I n  chronic C. pnerirnoniac infections the major 
obstacle is obtaining representative samples from the 
deep-sited proposed lesions. However, tome direct 
evidence of chronic C. pneumoriine infection (e.g. in 
arteriosclerosis) has already been publithed [64-711. 
Antigen detection from more easily available circulating 
immune complexes does not seein to be as sensitive as 
antibody detection, but at this moment it has not been 
studied sufficiently. 
Nucleic acid detection 
The prospect of direct diagnosis of chronic C. prreumo- 
nine infections seems to depend on NA detection 
methods. Problems to be tolved are: (1) how to obtain 
a proper sample; (2) how to process it to extract reactive 
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NAs in the proper condition; (3) how to neutralize 
interfering components in a biological sample; and (4) 
how to exclude contamination from the extremely 
sensitive test system. In situ hybridization can, 
moreover, determine the exact locality of a chronic 
C. pneumoniae infection. These problems are solvable. 
In chronic infections, NA detection methods will in 
future be able to resolve the problems associated not 
only with chronic C. pneumoniae infections, but also 
with chronic chlamydia1 infections in a broader sense 
[65,66,72,73]. The first report on the presence of 
C. pneumoniae NAs in circulating white blood cells has 
already appeared [74]. In future, this may become a 
routine method for diagnosing a chronic C. pneumoniae 
infection and monitoring the effect of treatment. 
CONCLUSIONS 
Diagnosis of acute and chronic C. pneumoniae infections 
seems at this moment to be insensitive and a matter of 
debate. Diagnosis of acute infections is reasonably well 
established in most laboratories. Chronic infections 
pose a different problem. Because of the recent demon- 
stration of the protective effect of antibiotic treatment 
in atherosclerosis patients with markers of C. 
pneumoniae infection [75,76], reliable, inexpensive 
methods for the diagnosis of chronic C. pneumoniae 
infections are urgently needed. 
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